Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label single-arm study of Kamada-Anti-SARS-CoV-2 in hospitalized non-ventilated COVID-19 pneumonia patients
MOH_2020-07-27_009173Phase 2Completed
- Sponsor
- Kamada Ltd.
- Start
- Jul 2020
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-SARS-CoV-2 polyclonal immunoglobulin in coronavirus disease 2019 (COVID-19) and pneumonia, sponsored by Kamada Ltd. Started Jul 2020; status: completed.
02
Drugs
anti-SARS-CoV-2 polyclonal immunoglobulin
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on MOH_2020-07-27_009173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-07-27_009173.